158 related articles for article (PubMed ID: 6342758)
1. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.
Kornstein MJ; Brooks JS; Elder DE
Cancer Res; 1983 Jun; 43(6):2749-53. PubMed ID: 6342758
[TBL] [Abstract][Full Text] [Related]
2. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cells in the host response to melanoma.
Kornstein MJ; Stewart R; Elder DE
Cancer Res; 1987 Mar; 47(5):1411-2. PubMed ID: 3815344
[TBL] [Abstract][Full Text] [Related]
4. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.
Lyle S; Salhany KE; Elder DE
Mod Pathol; 2000 Jan; 13(1):52-5. PubMed ID: 10658910
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
[TBL] [Abstract][Full Text] [Related]
6. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma.
Ruiter DJ; Bhan AK; Harrist TJ; Sober AJ; Mihm MC
J Immunol; 1982 Dec; 129(6):2808-15. PubMed ID: 6183345
[TBL] [Abstract][Full Text] [Related]
7. FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study.
Bozdogan N; Bozdogan O; Pak I; Atasoy P
Int J Dermatol; 2010 Jul; 49(7):761-7. PubMed ID: 20618494
[TBL] [Abstract][Full Text] [Related]
8. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
10. Association between natural killer cells and regression in melanocytic lesions.
McKay K; Moore PC; Smoller BR; Hiatt KM
Hum Pathol; 2011 Dec; 42(12):1960-4. PubMed ID: 21676435
[TBL] [Abstract][Full Text] [Related]
11. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
Hussein MR; Elsers DA; Fadel SA; Omar AE
J Clin Pathol; 2006 Mar; 59(3):316-24. PubMed ID: 16505286
[TBL] [Abstract][Full Text] [Related]
12. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
14. Infiltrating lymphocytes in benign and malignant naevomelanocytic lesions.
Flageul B; Bachelez H; Boumsell L; Degos L; Bensussan A
Nouv Rev Fr Hematol (1978); 1990; 32(1):9-11. PubMed ID: 2349086
[TBL] [Abstract][Full Text] [Related]
15. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 receptor expression in benign and malignant melanocytic skin lesions.
Kernohan NM; Sewell HF
J Pathol; 1989 Apr; 157(4):315-9. PubMed ID: 2785590
[TBL] [Abstract][Full Text] [Related]
17. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
18. Nevi, other than dysplastic and Spitz nevi.
Cochran AJ; Bailly C; Paul E; Dolbeau D
Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
[TBL] [Abstract][Full Text] [Related]
19. Association between sialyl Lewis(a) expression and tumor progression in melanoma.
Kageshita T; Hirai S; Kimura T; Hanai N; Ohta S; Ono T
Cancer Res; 1995 Apr; 55(8):1748-51. PubMed ID: 7712483
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
